NovaBiotics' proprietary technology has demonstrated antimicrobial efficacy against a number of clinically and economically significant fungal and bacterial pathogens such that the technology has the potential to be applied for the treatment of a range of diseases and infectious conditions.

The lead compound, NP213, is a topical treatment (applied in lacquer form) for nail fungus (onychomycosis/tinea unguim) and various other candidate therapies comprise a preclinical pipeline of candidate therapeutics, including those for systemic fungal infections, acne, cystic fibrosis-associated lung infections and hospital-acquired bacterial infections.

“We are facing a relentless increase in antibiotic resistance across all classes of drug,” Prof G Poste

NovaBiotics also has an active interest in the following infectious disease areas, all of which are key target applications for our novel platform technology.

• Dermal infections (fungal and bacterial)
• Opportunistic/secondary dermal infections associated with eczema, burns, ulcers and complex wounds
• Gastrointestinal infections
• Oral infections
• Urogenital infections

NovaBiotics' research and development program is driven from both an immunological and microbiological foundation. In parallel with developing treatments for infectious diseases and conditions, NovaBiotics Ltd is striving to underpin the cellular and molecular basis for patient susceptibility to the infectious diseases the company is targeting.

“If unable to mount an appropriate defence response, the host is open to any number of infections”

Providing insights into the basis for infectious disease not only strengthens NovaBiotics' rational drug design-based approach to research and development, but provides the opportunity to identify novel therapeutic targets. In addition to our interest in human health, NovaBiotics' is also interested in veterinary and other applications for our proprietary novel antimicrobial technology.